

ORIGINAL ARTICLE

Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media

YUKIKO IINO, MARIKO HARA, MASAYO HASEGAWA, SHINGO MATSUZAWA, AKIHIRO SHINNABE, HIROMI KANAZAWA & NAOHIRO YOSHIDA

Department of Otolaryngology, Jichi Medical University Saitama Medical Center, Saitama, Japan

Abstract

Conclusions: Eosinophil cationic protein (ECP) concentrations in middle ear effusion (MEE) in patients with eosinophilic otitis media (EOM) were significantly decreased at 3 months after the administration of omalizumab from the baseline level ($p < 0.05$). This study provides new evidence that omalizumab reduces eosinophilic inflammation in the middle ear and that the reduction of ECP may not be caused by suppression of interleukin (IL)-5 production in the middle ear mucosa. **Objective:** EOM is an intractable otitis media characterized by a highly viscous effusion containing eosinophils. We recently reported that anti-IgE therapy using omalizumab was efficacious in the treatment of EOM. To clarify the underlying mechanism, we determined changes in biomarkers in MEE related to eosinophilic inflammation after therapy. **Methods:** Nine patients with EOM received the anti-IgE agent omalizumab for 3 months. Among them, five patients continued anti-IgE therapy for longer than 1 year. Eight EOM patients without administration of omalizumab were also included in the study as controls. The concentrations of eosinophilic inflammatory markers such as ECP, IgE, IL-4, and IL-5 in MEE were measured before and after the administration of omalizumab. **Results:** After 3 months of omalizumab therapy, the ECP concentration in MEE was significantly reduced from the baseline level ($p < 0.05$), while no significant change of ECP in the serum was observed. The concentrations of IL-4 and IL-5 in MEE showed no significant change before and after the therapy in EOM patients treated with omalizumab.

Keywords: Anti-IgE therapy, eosinophilic cationic protein, ECP, IgE, interleukin (IL)-4, IL-5

Introduction

Eosinophilic otitis media (EOM) is an intractable otitis media characterized by the presence of a highly viscous yellow effusion containing eosinophils. EOM is mainly associated with bronchial asthma. In 2011, diagnostic criteria for EOM were established by the EOM study group [1]. The major criterion of EOM is otitis media with effusion or chronic otitis media with eosinophil-dominant effusion. The minor criteria are as follows: (1) highly viscous middle ear effusion (MEE); (2) resistance to conventional treatment for otitis media; (3) association with bronchial asthma; and (4) association with nasal polyposis. Definitive cases are defined as positive for the major criterion

plus two or more of the minor criteria. However, Churg-Strauss syndrome and hypereosinophilic syndrome are excluded. EOM is an intractable and persistent disease, and it also presents a high risk for development of severe hearing loss. In our previous study, the incidence of deterioration of bone conduction and total deafness was 59% and 6%, respectively [1].

In the middle ear of patients with EOM, active eosinophilic inflammation appears to be present because eosinophil cationic protein (ECP) levels in MEE and the number of EG2 immunopositive cells in the middle ear mucosa are significantly higher in EOM patients than in control patients with common otitis media [2]. Currently, the most reliable

Correspondence: Yukiko Iino MD PhD, Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan. Tel: +81 48 647 2111. Fax: +81 48 648 5188. E-mail: yiino@jichi.ac.jp

(Received 11 September 2013; accepted 13 November 2013)

ISSN 0001-6489 print/ISSN 1651-2251 online © 2014 Informa Healthcare
DOI: 10.3109/00016489.2013.868601

treatment for EOM is systemic and topical administration of corticosteroids, similar to that for bronchial asthma. Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, is used as an anti-IgE agent with clinical benefits in the treatment of moderate to severe bronchial asthma. Recently, we reported that anti-IgE therapy using omalizumab was efficacious for patients with EOM associated with bronchial asthma [3]. However, the mechanism underlying the effectiveness of omalizumab for EOM has not been determined yet. In this study, we examined changes in some biomarkers related to eosinophilic inflammation in MEE of patients treated with omalizumab to clarify the mechanism.

Material and methods

Patients

Nine patients with EOM who received anti-IgE therapy using omalizumab were included in the present study. The patients were six women and three men aged 33–69 years (mean $\pm$ SD, 55.9 ± 11.8 years) at the time of administration of omalizumab (omalizumab group). Eight patients with EOM without anti-IgE therapy were included in the study as controls. All of the patients had bronchial asthma, which had been treated by respiratory specialists. They were diagnosed with EOM by otologists on

the basis of previously reported diagnostic criteria [1]. The baseline characteristics of the EOM patients in both groups are shown in Table I. Written informed consent was obtained from all patients before enrolment in the study. This study was approved by the Ethics Committee of Jichi Medical University Saitama Medical Center (study no. RIN 10-11).

Treatments

Omalizumab was given to the nine patients with EOM in the omalizumab group. The dosage of omalizumab was individually determined based on the pretreatment level of total serum IgE and body weight, according to dosing tables that approximately reflected the following formula: 0.016 mg/kg per IU/ml of IgE per 4 weeks. Omalizumab was administered by subcutaneous injections every 2 or 4 weeks. All of the patients in both groups continued their previous treatments for bronchial asthma and EOM during the study (Table I). They were all treated with inhaled corticosteroids with or without long-acting beta 2-adrenergic agonists and oral leukotriene receptor antagonists or suplatast tosilate for bronchial asthma. All of the patients, except for one in each of the groups, had also experienced frequent asthma exacerbations and continuously or frequently taken oral corticosteroids, in addition to inhaled corticosteroid therapy. One patient in the omalizumab

Table I. Baseline characteristics of the patients.

Characteristic	Omalizumab group	Control group	<i>p</i> value
No. of patients	9	8	...
Sex (F:M)	6:3	5:3	NS
Age (years, mean $\pm$ SD)	55.9 ± 11.8	56.5 ± 14.4	NS
Associated diseases			
Aspirin intolerance	4	3	NS
Chronic rhinosinusitis	9	6	NS
Nasal polyposis	6	6	NS
Bacterial infection in MEE	3	3	NS
Treatments			
Inhaled corticosteroids	9	8	NS
Intranasal corticosteroids	8	7	NS
Intratympanic TA	9	8	NS
Systemic corticosteroids	8	8	NS
Daily	1	1	
Sometimes on exacerbation	7	7	
Leukotriene receptor antagonists	8	7	NS
Suplatast tosilate*	1	1	NS

MEE, middle ear effusion; NS, not significant; TA, triamcinolone acetone.

*Th2 cytokine inhibitor.

Table II. Total dosage of prednisolone (mg) administered for 1 month before the sampling of middle ear effusion.

Patient	Baseline	3 months	1 year
Omalizumab group			
T.K.	150	150	...
Y.A.*	240	30	0
S.K.*	0	60	0
T.Y.*	30	0	0
Control group			
T.R.	60	60	...
Y.Y.	17.5	75	...

*Patients who continued the omalizumab therapy for more than 1 year.

group had taken 5 mg of prednisolone daily, and one patient in the control group had taken 2 mg of prednisolone daily. The total dosages of prednisolone for 1 month before the sampling of MEE in both groups are summarized in Table II. For EOM, intratympanic instillation of triamcinolone acetonide was used as the baseline treatment when MEE or otorrhea recurred. Systemic administration of antibiotics was given to the patients when bacterial infection was detected in the MEE. Five patients treated by omalizumab continued the therapy for more than 1 year. Although the remaining four patients did not show the complete resolution of EOM, they discontinued the therapy at 3 months for economic reasons.

Preparation of MEE

MEE samples were collected using a Jun-Tym-Tap middle ear fluid aspirator/collector (Xomed, Jacksonville, FL, USA) or using forceps if the effusion was too sticky to remove by the former device. A total of 50–100 mg of an effusion sample was suspended in 1 ml of saline until the fluid became homogeneous using a homogenizer at room temperature. The fluid samples were allowed to stand for 60–120 min and were then centrifuged at 1000–1350 *g* for 10 min. The resultant

supernatant was collected and stored at -80°C until measurement of biomarkers.

Measurement of ECP, IgE, interleukin (IL)-4, and IL-5 concentrations in MEE

Concentrations of ECP, IgE, IL-4, and IL-5 in MEE samples were measured by fluorescence enzyme immunoassay. The detection limits of the measurement methods were 2.0 mg/L for ECP, 5.0 IU/ml for IgE, 2.0 pg/ml for IL-4, and 3.9 pg/ml for IL-5.

Measurements of biomarkers in serum

We also monitored the concentrations of ECP and total IgE in the serum before and after therapy. Serum concentrations of ECP and total IgE were measured by fluorescence enzyme immunoassays.

Statistical analysis

Statistical analysis was carried out using the chi-squared test, and paired and unpaired *t* tests. *p* values < 0.05 were considered significant.

Results

Clinical evaluation of anti-IgE therapy

No adverse events were observed during the administration of omalizumab in any of the patients. Among the nine patients who received anti-IgE therapy, six showed a reduction in MEE. After the 1-year follow-up period, six of nine patients showed a large reduction in the need for intratympanic instillation of triamcinolone acetonide. In contrast, patients in the control group continued their previous therapy and their symptoms did not change.

Concentrations of ECP, IgE, IL-4, and IL-5 in MEE

The concentrations of ECP in MEE at baseline and 3 months after the therapy are shown in Table III. Extremely high ECP concentrations were detected in

Table III. ECP concentrations ($\mu\text{g/L}$) in middle ear effusion and serum in the omalizumab group and control group.

Factor	Omalizumab		Control	
	MEE	Serum	MEE	Serum
Baseline	64 236 (1853–231 150)	27 (7–86)	18228 (2244–72 154)	19 (10–21)
3 months	33921 (1598–139 000)	21 (3–52)	86012 (2390–348 514)	20 (10–48)
<i>p</i> value	< 0.05	NS	NS	NS

Values shown are average (range) concentrations for nine patients in the omalizumab group and eight patients in the control group. ECP, eosinophil cationic protein; MEE, middle ear effusion; NS, not significant.

Table IV. IgE concentrations (IU/ml) in middle ear effusion and serum in the omalizumab group and control group.

Factor	Omalizumab		Control	
	MEE	Serum	MEE	Serum
Baseline	1588 (65–7438)	252 (57–637)	1004 (36–2010)	302 (37–1110)
3 months	3369 (53–11 319)	603 (168–1300)	964 (256–1359)	300 (48–1000)
<i>p</i> value	NS	< 0.01	NS	NS

Values shown are average (range) concentrations for nine patients in the omalizumab group and eight patients in the control group. MEE, middle ear effusion; NS, not significant.

the MEE of all patients with EOM in both groups. ECP concentrations in MEE were almost 10^3 times those of the serum concentrations in each patient. At 3 months after the administration of omalizumab, ECP concentrations were significantly decreased from baseline levels ($p < 0.05$), while no significant change in serum ECP concentration was noted at 3 months. In the control patients, ECP concentrations at 3 months were the same as those at baseline (Table III).

Table IV shows the change of IgE concentration in MEE and serum in the omalizumab group and the control group. An increase in IgE concentrations in MEE was also found at 3 months, as observed in serum, but this difference was not significant.

No significant change in IL-4 concentrations was observed between baseline and at 3 months of therapy in the omalizumab and control groups (Table V). IL-5 concentrations in MEE were under the detectable limit in two patients at baseline and in four patients at 3 months in the omalizumab group. In the control group, two patients at baseline and one patient at 3 months had IL-5 concentrations less than the detectable limit in the MEE (Table V).

Changes in ECP, IgE, IL-4, and IL-5 in MEE of patients treated by omalizumab for longer than 1 year

Among the five patients who continued the therapy for more than 1 year, one patient showed complete resolution of MEE at 3 months. Although the remaining

four patients had reduced recurrence of effusion, samples could be taken when MEE recurred at around 1 year after therapy. The changes in markers of MEE of the four patients are shown in Figure 1. There was no significant change in concentrations of these markers in the four patients during the therapy. A patient with increased levels of ECP and IgE at 1 year was well controlled by omalizumab for bronchial asthma and EOM. However, the effusion recurred at about 1 year. The middle ear mucosa of this case stayed almost normal (grade 1) [3] during the omalizumab therapy. Another case with increased level of ECP was well controlled for asthma but not for EOM, although the incidence of MEE had become less. The middle ear mucosa of the patient was edematous and slightly swollen (grade 2) [3], showing no significant change during the therapy. There was no significant correlation between the systemic administration of prednisolone and the levels of biomarkers. For example, one patient who had received 240 mg of prednisolone at baseline and 30 mg of prednisolone at 3 months showed marked reduction of ECP level at 3 months from the baseline level.

Discussion

The anti-IgE monoclonal antibody using omalizumab has been approved in therapy for moderate to severe bronchial asthma. This antibody binds to free IgE and prevents it from binding to cell surface high-affinity FcεR1 receptors on mast cells, basophils, and

Table V. IL-4 and IL-5 concentrations in middle ear effusion (MEE) in the omalizumab group and control group.

Factor	IL-4 (pg/ml)		IL-5 (pg/ml)	
	Omalizumab	Control	Omalizumab	Control
Baseline	144 (38–466)	175 (39–606)	1261 (UD–6220)	897 (UD–1459)
3 months	239 (27–680)	149 (70–189)	898 (UD–1680)	750 (UD–1816)
<i>p</i> value	NS	NS	NS	NS

Values shown are average (range) concentrations for nine patients in the omalizumab group and eight patients in the control group. IL, interleukin; NS, not significant; UD, under detection limit.




Figure 1. Concentrations of eosinophil cationic protein (ECP), IgE, interleukin (IL)-4, and IL-5 in middle ear effusions of four patients treated with omalizumab for more than 1 year.

eosinophils. This results in IgE cross-linking, and cell activation cannot occur. A large number of studies have shown that omalizumab causes a significant decrease in the number of asthma exacerbations and emergency room visits [4]. A recent meta-analysis of eight trials ($n = 3429$ participants) showed the efficacy and safety of omalizumab in adults, adolescents, and children with moderate to severe asthma [5].

EOM is mostly associated with bronchial asthma, and recent diagnostic criteria for EOM include the association of bronchial asthma as a minor criterion. The effusion of EOM is highly viscous, containing many eosinophils and high concentrations of ECP and IL-5 [2]. We recently showed that significantly higher IgE concentrations were detected in MEE than in serum of EOM patients, regardless of the presence of atopic predisposition [6]. This finding suggests that IgE may be locally produced in the middle ear mucosa rather than being derived from the serum. EOM is not only refractory, but also causes deterioration of bone conduction hearing levels, particularly at high frequencies. High tone loss is significantly associated with high concentrations of IgE and ECP in MEE [6]. Therefore, anti-IgE therapy may also be effective for

controlling EOM and for preventing deterioration of hearing.

Recently, we reported the clinical efficacy of anti-IgE therapy using omalizumab for EOM associated with bronchial asthma [3]. Patients who received omalizumab showed improvement in ear symptom scores evaluated by a questionnaire, as well as in clinical scores, including otoscopic findings and systemic and local administration of corticosteroids. In addition, deterioration of bone conduction hearing levels was found less frequently in the omalizumab group than in the control group. In the omalizumab group, one patient showed bilateral deterioration of the bone conduction hearing level beyond 15 dB at the mean speech range or 4 kHz. On the other hand, in the control group, the bone conduction hearing level worsened in seven ears of four patients at the mean speech range or 4 kHz at 1 year. Therefore, anti-IgE therapy is clinically and audiotologically effective for EOM, as well as for bronchial asthma.

Eosinophilia is a typical characteristic of asthma-related inflammatory diseases, including EOM. A meta-analysis of five randomized, double-blind, placebo-controlled studies showed that a significant

reduction in the eosinophil count from baseline was observed in patients with allergic asthma treated with omalizumab compared with those administered placebo [7]. In addition to reduction of peripheral blood eosinophils, omalizumab has also been shown to reduce eosinophilia in sputum and bronchial biopsies [8]. In our previous study, the eosinophil count tended to decrease after 3 months of anti-IgE therapy [3]. This reduction in eosinophilia is probably due to a powerful induction of apoptosis of eosinophils. Omalizumab can significantly increase the staining of peripheral eosinophils with apoptotic markers, such as annexin V [9]. The pro-apoptotic action of omalizumab is associated with a decrease in T-cell production of granulocyte macrophage colony stimulating factor (GM-CSF), an important mediator involved in eosinophil growth and survival. GM-CSF is released by CD4⁺ cells, and plays an important role in late-phase allergic responses that are characterized by eosinophil influx to the airways [9].

The present study showed that ECP concentrations in MEE were significantly decreased after therapy, although the serum ECP concentration failed to show the significant change. This suggested a decreased number of migrating eosinophils in MEE after therapy because ECP is derived from eosinophils and is a marker protein of eosinophilic inflammation. The apoptosis of eosinophils in the middle ear mucosa may occur after the administration of omalizumab. Indeed, the same findings regarding apoptosis of the eosinophils were observed in the middle ear mucosa when triamcinolone acetonide was applied to the middle ear [2].

Total IgE concentrations in the serum was significantly elevated from baseline at 3 months in the present study. MEE concentrations were also slightly elevated after therapy, but this difference was not statistically significant. Total IgE concentrations appear to be increased after the administration of omalizumab because this value includes free IgE, as well as omalizumab-bound IgE [10]. However, a newly available recovery enzyme-linked immunoabsorbent assay for quantifying free serum IgE demonstrated a large reduction in free serum IgE concentrations in patients with severe asthma after therapy [11]. A recent study showed that early elevation of total IgE to more than 250 IU/ml at 3 months from baseline may be used as a predictor of future responders to omalizumab in terms of the exacerbation rate [12].

The most dramatic effect of omalizumab is its ability to reduce levels of the high-affinity IgE receptor FcεR1 in basophils in peripheral blood by approximately 90% in 1 week and by 99% with longer administration [13–15]. Signaling through FcεR1 causes synthesis and release of substantial amounts of Th2 cytokines, such as IL-4, IL-5, and IL-13,

which are critical for initiating and maintaining allergic responses. Indeed, omalizumab reduces circulating levels of IL-13, IL-4, and IL-8, in addition to reducing circulating eosinophil counts [16]. IL-4 has been shown to promote class switching to IgE in B cells. In bronchial mucosa, a significantly greater reduction in cells immunostained for IL-4 was observed in the omalizumab-treated group than in the placebo group [8]. IL-13 is also an important cytokine in IgE production and hyper-reactivity in bronchial mucosa of asthmatic patients. Noga et al. [16] reported that omalizumab induced down-regulation of the inflammatory cytokines IL-2 and IL-13, while no significant difference in IL-5, interferon-γ, and tumor necrosis factor (TNF)-α was observed between the omalizumab-treated group and the control group. In an *in vitro* study, Oliver et al. [17] showed a reduction in IL-4, IL-13, and IL-8 synthesis mediated by FcεR1 in basophils by omalizumab. Roth et al. [18] also showed that omalizumab inhibits the production of IL-4, IL-6, IL-8, and TNF-α in asthmatic airway smooth muscle cells stimulated by IgE. Taken together, these findings suggest that treatment with omalizumab reduces peripheral and bronchial tissue eosinophil counts, as well as diminishing the release of a variety of proinflammatory mediators, such as GM-CSF, IL-2, IL-4, IL-5, and IL-13 [19].

Our previous study also showed that ant-IgE treatment using omalizumab was clinically effective for EOM [3]. To clarify the mechanism, we analyzed some biomarkers in MEE during omalizumab therapy. Our pilot study showed that IL-2, IL-13, and IL-33 concentrations in MEE were under the detectable limit in most of the patients with EOM. Although IL-4 and IL-5 were detected in MEE of patients, no significant changes in their concentrations were observed in MEE during the administration of omalizumab. We previously reported that ECP and IL-5 concentrations are positively correlated in MEE and that locally produced IL-5 may play a crucial role in the accumulation of eosinophils in the middle ear [2]. A significant reduction in ECP concentrations was observed 3 months after omalizumab therapy, regardless of the change in IL-5 concentrations. These results indicate that the reduction of ECP may be due to other mechanisms, such as down-regulation of GM-CSF in mast cells and basophils in the middle ear mucosa.

In conclusion, we provide the first report that ECP concentrations in MEE are significantly reduced after administration of omalizumab. This finding suggests that omalizumab can reduce migration of eosinophils to the middle ear. The effectiveness of omalizumab on EOM may not be caused by suppression of IL-5 production in the middle ear mucosa. Further

study is required to determine the change in expression of these cytokines and the FcεR1 receptor in the middle ear mucosa.

Acknowledgments

This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

- [1] Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. *Auris Nasus Larynx* 2011;38:456–61.
- [2] Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S. Eosinophil chemoattractant in middle ear of patients with eosinophilic otitis media. *Clin Exp Allergy* 2005;35:1370–6.
- [3] Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H, et al. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. *Otol Neurotol* 2012;33:1218–24.
- [4] Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. *Chest* 2011;139:28–35.
- [5] Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2006;CD003559.
- [6] Iino Y, Usubuchi H, Kodama K, Kanazawa H, Takizawa K, Kanazawa T, et al. Eosinophilic inflammation in the middle ear induces deterioration of bone conduction hearing level in patients with eosinophilic otitis media. *Otol Neurotol* 2010;31:100–4.
- [7] Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. *J Asthma* 2012;49:144–52.
- [8] Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. *Am J Respir Crit Care Med* 2004;170:583–93.
- [9] Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. *J Allergy Clin Immunol* 2006;117:1493–9.
- [10] Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. *J Immunol Methods* 2005;303:81–91.
- [11] Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. *Respir Med* 2012;106:1494–500.
- [12] Dal Negro RW, Guerriero M, Micheletto C, Ognella S, Visconti M. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study. *J Asthma* 2011;48:437–41.
- [13] MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of FcεR1 expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol* 1997;158:1438–45.
- [14] Saini SS, MacGlashan DW, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FcεR1 surface densities and mediator release by anti-IgE-infusion is reversible in vitro and in vivo. *J Immunol* 1999;162:6893–900.
- [15] Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini SS. Omalizumab-induced reductions in mast cell FcεR1 expression and function. *J Allergy Clin Immunol* 2004;114:527–30.
- [16] Noga O, Hanf G, Kunkei G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. *Int Arch Allergy Immunol* 2003;131:46–52.
- [17] Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, et al. Reduced FcεR1-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. *Int Arch Allergy Immunol* 2010;151:275–84.
- [18] Roth M, Tamm M. The effect of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. *Ann Allergy Asthma Immunol* 2010;104:152–60.
- [19] Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. *Allergy* 2009;64:1728–36.